Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK/T-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH)
Plain-language summary
This Phase 1, Phase 2 trial is studying Mitoxantrone liposome, Etoposide, and other medications for people with NK/T-cell lymphoma. The study starts with lower doses to find the safest effective dose before testing in more people. This trial does not currently list US sites.
Who can join (key eligibility)
- Age 18 Years or older
- See full trial listing for complete eligibility
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Mitoxantrone liposome (DRUG): In the Phase Ib part, 3 patients will be enrolled at the starting dose of liposomal mitoxantrone: 18 mg/m²/d on day 1, every 3 weeks (q3w). If no DLT occurs, the recommended phase 2 dose (RP2D) will be 18 mg/m²/d on day 1 q3w. If DLT occurs, the dose will be de-escalated sequentially (18→16→14→12 mg/m²/d on day 1 q3w). | Etoposide (DRUG): 100mg/m²/d，d1、d8，q3w | Pegaspargase (PEG) Asparaginase (DRUG): 2000IU/m²/d，d5，q3w | methylprednisolone (DRUG): 15mg/kg/d，d1-3 7.5mg/kg/d，d4-7 1mg/kg/d d8-14 10mg/d，d15-21 | golidocitinib (DRUG): 150mg/d，d1-d21，q3w
- Drugs / treatments
- Mitoxantrone liposome, Etoposide, Pegaspargase (PEG) Asparaginase, methylprednisolone, golidocitinib
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details